What Percentage Of Its Revenue Could J&J Lose Solely Due To Patent Losses Over The Next 5 Years?
- J&J Could Lose ~ 25% Of Its Pharma Revenue Due To Patent Losses By 2020
- The Gap Will Be Filled By Growing & Pipeline Drugs
Relevant Articles
- What’s Next For Johnson & Johnson Stock After Beating Q1 Earnings?
- Here’s What To Expect From Johnson & Johnson’s Q1
- What’s Next For Johnson & Johnson Stock After A 6% Decline In A Month?
- Is Johnson & Johnson Stock A Better Pick Over AbbVie?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
The CAGR calculations assume ~10% annual revenue decline for Remicade and ~15%-20% annual revenue decline for other drugs following their respective patent expiry
Have more questions about Johnson & Johnson? See the links below.
- How J&J’s Increased Focus On Pharmaceuticals Has Helped Its Financials?
- Drugs, Devices, Consumer: What’s Johnson & Johnson’s Revenue and Earnings breakdown?
- What’s J&J’s Fundamental Value Based On Expected 2015 Results?
- How Increased Focus On Pharmaceuticals In The Last 5 Years Has Helped J&J?
- By How Much Can J&J’s Revenue And EBITDA Grow Over The Next 3 Years?
- What’s J&J’s Fundamental Value Based On Expected 2015 Results?
- How Much Revenues Can J&J’s Phase 3 Pipeline Add By 2020?
- If Remicade Biosimilar Hits The U.S. Market In 2017, Does J&J Face Any Meaningful EPS Decline?
Note: The figures mentioned are approximate values to help our readers remember and grasp the concept more intuitively. For accurate figures, please refer to our complete analysis for Johnson & Johnson
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)